PREVISE FUELS GROWTH OF ITS BARRETT'S ESOPHAGUS RISK STRATIFICATION TEST WITH A COMPETITIVE $1.8M SBIR GRANT
BALTIMORE, Oct. 12, 2023 /PRNewswire/ -- Previse, maker of Esopredict, a clinically available test that analyzes methylation of biomarkers to assess the risk of esophageal cancer developing in patients with Barrett's esophagus and currently provides GI physicians with results within one week, was awarded a prestigious and highly competitive $1.8M Direct to Phase II SBIR (Small Business Innovation Research) grant by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH).
- Esopredict™, Previse's Flagship Product, Awarded NIH Direct to Phase II SBIR Grant to Drive Further Studies of Commercially Available Barrett's Esophagus Prognostic Test.
- Securing the SBIR grant for this project involved Previse collaborating with investigators at Johns Hopkins University School of Medicine to submit intensive research and commercialization plans to the NIH, outlining the path Previse is taking to accelerate the adoption of the Esopredict test.
- Esopredict is a game-changing assay rooted in highly accurate methylation-based analysis, which empowers gastroenterologists to predict the risk of progression to high-grade dysplasia or esophageal adenocarcinoma in patients with Barrett's esophagus.
- Previse CEO Daniel Lunz said: "This substantial grant awarded by the NIH underlines the potential impact of Previse's Esopredict assay and methylation technology.